Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT03788746 · ClinicalTrials.gov registry record

Prevalence of PD-L1 Expression in Patients With Advanced Urothelial Carcinoma

A clinical trial of Urothelial Carcinoma, sponsored by AstraZeneca.

Completed
Registry status
181
Enrollment target
20
Study locations

NCT03788746 is a study of Urothelial Carcinoma that has completed, run by AstraZeneca. The registered enrollment target is 181 participants, below the 237-participant average among 85 other Urothelial Carcinoma trials with a reported enrollment target (24% lower). The trial reports 20 study locations across 8 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT03788746, a study of Urothelial Carcinoma, has completed, sponsored by AstraZeneca.

COMPLETED
Registry status
181 participants
Enrollment target
20
Study locations

Study Summary

The purpose of this study is to assess the prevalence of pre-treatment tumor tissue PD-L1 expression in patients diagnosed with advanced urothelial carcinoma.

Conditions Studied

Urothelial Carcinoma

Study Locations (20)

California

  • Research Site - Glendale
  • Research Site - Los Angeles
  • Research Site - Los Angeles
  • Research Site - Monterey
  • Research Site - Santa Rosa

Illinois

  • Research Site - Geneva
  • Research Site - Harvey
  • Research Site - Lake Barrington
  • Research Site - Naperville

Florida

  • Research Site - Boca Raton
  • Research Site - Hialeah
  • Research Site - Jacksonville

Colorado

  • Research Site - Denver
  • Research Site - Englewood

Connecticut

  • Research Site - Hartford
  • Research Site - Stamford

Georgia

  • Research Site - Augusta
  • Research Site - Roswell

Arkansas

  • Research Site - Little Rock

Indiana

  • Research Site - Greenwood

Trial Details

FieldValue
Enrollment Target 181 participants
Start Date 2019-01-17
Est. Completion 2023-05-25

Sponsor

AstraZeneca

1,285 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT03788746

The ClinicalTrials.gov registry entry for NCT03788746 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 181 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 237-participant average among 85 other Urothelial Carcinoma trials with a reported enrollment target (24% lower). The listed sponsor is AstraZeneca, which has 1,285 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Urothelial Carcinoma appearing as the primary indexed condition, and to 0 interventions.

NCT03788746 reports 20 study locations spanning 8 distinct geographic areas - top geographies include California, Illinois, Florida.

Frequently Asked Questions

What is clinical trial NCT03788746 about?

NCT03788746 is a clinical study titled "Prevalence of PD-L1 Expression in Patients With Advanced Urothelial Carcinoma". The purpose of this study is to assess the prevalence of pre-treatment tumor tissue PD-L1 expression in patients diagnosed with advanced urothelial carcinoma.

What is the current status of trial NCT03788746?

This trial is currently completed. The enrollment target is 181 participants. The study started on 2019-01-17. Estimated completion is 2023-05-25.

What conditions does trial NCT03788746 study?

This clinical trial studies the following conditions: Urothelial Carcinoma.

Who is sponsoring clinical trial NCT03788746?

This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT03788746 being conducted?

This trial has 20 study locations across Arkansas, California, Colorado, Connecticut, Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Urothelial Carcinoma

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Urothelial Carcinoma

All registered trials for this condition

Arkansas

All trials with a study site in Arkansas

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.